STAT+: Trump boast on drug pricing policy overstated state-level interest in federal program
Stat News • 9/17/2026 – 9/24/2026
Summary
No summary yet.
Advertisement
Cluster Activity
1
2
1
2026-09-172026-09-24
Lindy Score Breakdown (V4.2)
8h
Age
3
Sources
from cluster
1
Hours Since Seen
Final Score40/100
CategoryLindy
StatusActive
Recency Multiplier99% (0.5^1/48)
Hero EligibleYes
Story Timeline
- 2026-09-17
- 2026-09-18
- 2026-09-24STAT+: Trump boast on drug pricing policy overstated state-level interest in federal program (current)
Score BreakdownRisk 55
Source Reputation: Low-trust source (4/20 pts)
Consensus: Emerging consensus: 3 sources
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Same Story from 4 sources
Breaking Similar stories
STAT+: Why an influential GOP health policy expert still backs the Medicaid cuts — and which policy target is next
Stat News • 2 days ago
STAT+: Did the Trump administration just cut Novo a huge financial win?
Stat News • 2 days ago
STAT+: Drugmakers, biotech VCs show ‘reinvigorated’ interest in osteoporosis treatments
Stat News • 1 day ago
STAT+: HHS unveils new initiatives to reduce animal testing in drug development
Stat News • 1 day ago
STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
Stat News • 2 days ago
STAT+: The rise of the AI-native radiology practice
Stat News • Today
STAT+: Nominee to lead FDA aims to speed up medical research, combat China’s rise
Stat News • Today
STAT+: Ohio governor’s race is a battle over Covid, health costs, and trust in science
Stat News • 2 days ago
STAT+: Epic’s mortality model, and Omada’s future products
Stat News • 2 days ago
STAT+: UnitedHealth, CVS push back on Medicare plan to curb remote patient monitoring
Stat News • 1 day ago